Quarterly report pursuant to Section 13 or 15(d)

Note 10 - Shareholders' Equity

v3.22.2.2
Note 10 - Shareholders' Equity
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

10.

Shareholders Equity

 

Authorized capital stock

 

The Company has authorized share capital of an unlimited number of voting common shares, and the shares do not have a stated par value.

 

Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company's annual general meeting and any special meeting.

 

Equity issued during the nine months ended September 30, 2022

 

During the nine months ended September 30, 2022, we did not issue any common shares or other equity securities other than stock options and deferred stock units.

 

Equity issued during the nine months ended September 30, 2021

 

On September 26, 2021, we issued and sold an aggregate 7,653,060 common shares in a securities purchase agreement at a purchase price of $3.92 per share in a private placement to ten accredited investors. As a result of the offering, we received gross proceeds of $30.0 million, which resulted in net proceeds to us of approximately $29.9 million, after deducting the offering expenses.

 

In connection with the September 2021 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on October 5, 2021 and declared effective by the SEC on October 14, 2021. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered “Registrable Securities” under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.

 

 

During the nine months ended September 30, 2021, 40,000 common shares were issued upon the exercise of options for gross proceeds of $244,000, with an aggregate intrinsic value of $132,000, and no warrants were exercised.

 

Shares reserved

 

Common shares reserved for future issuance are as follows:

 

   

September 30, 2022

 

Common shares issuable upon exercise of employee and non-employee stock options

    2,775,998  

Common shares issuable upon settlement of deferred stock units

    134,402  

Common shares issuable upon exercise of common share purchase warrants

    265,000  

Shares available for grant under the 2019 Omnibus Incentive Plan

    2,014,010  

Shares available for grant under the 2021 Employment Inducement Incentive Plan

    535,000  

Total

    5,724,410